During the last three months, 7 analysts shared their evaluations of 4D Molecular Therapeutics FDMT, revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 4 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 3 | 0 | 0 | 0 |
Analysts have recently evaluated 4D Molecular Therapeutics and provided 12-month price targets. The average target is $45.43, accompanied by a high estimate of $63.00 and a low estimate of $36.00. This current average reflects an increase of 10.35% from the previous average price target of $41.17.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of how financial experts perceive 4D Molecular Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Luca Issi | RBC Capital | Maintains | Outperform | $40.00 | $40.00 |
| Matthew Caufield | HC Wainwright & Co. | Maintains | Buy | $36.00 | $36.00 |
| Matthew Caufield | HC Wainwright & Co. | Maintains | Buy | $36.00 | $36.00 |
| Luca Issi | RBC Capital | Raises | Outperform | $40.00 | $35.00 |
| Gena Wang | Barclays | Announces | Overweight | $45.00 | - |
| Kostas Biliouris | BMO Capital | Lowers | Outperform | $63.00 | $70.00 |
| Nalin Tejavibulya | Jefferies | Raises | Buy | $58.00 | $30.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 4D Molecular Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 4D Molecular Therapeutics compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of 4D Molecular Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of 4D Molecular Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on 4D Molecular Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know 4D Molecular Therapeutics Better
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
4D Molecular Therapeutics's Financial Performance
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: 4D Molecular Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -90.6%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: 4D Molecular Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -115717.86%, the company may face hurdles in effective cost management.
Return on Equity (ROE): 4D Molecular Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.13% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -6.68%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
The Core of Analyst Ratings: What Every Investor Should Know
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
